

Pubblicazioni :

1. Locati LD, Quattrone P , **Bossi P**, Marchianò AV , Cantù G , Licitra L. "A complete remission with androgen deprivation therapy in a recurrent androgen receptors expressing adenocarcinoma of the parotid gland". **Ann Oncol, 2003; 14 (8): 1327-8.**
2. Sanguineti G, **Bossi P**, Pou A, Licitra L. "Timing of chemoradiotherapy and patient selection for locally advanced nasopharyngeal carcinoma". **Clin Oncol, 2003; 15: 451-60.**
3. Licitra L, **Bossi P**, Locati L, Zunino F. "Cisplatin and fluorouracil concurrent to radiotherapy in nasopharyngeal cancer: is the schedule compatible?" **J Clin Oncol 2004; 22: 377**
4. Licita L, Locati LD, **Bossi P**, Cantù G "Head and neck tumors other than squamous cell carcinomas" . **Curr Opin Oncol 2004 May; 16: 236-41**
5. Palazzi M, Guzzo M, **Bossi P**, Tomatis S, Cerrotta A, Cantù G, Locati LD, Licitra L "Regionally advanced nasopharyngeal carcinoma: long-term outcome after sequential chemotherapy and radiotherapy" . **Tumori 2004; 90: 60-65**
6. Licitra L, Locati LD, **Bossi P**. "Head and neck cancer." **Ann Oncol 2004; 15 Suppl 4: 267-73.**
7. Locati LD, Rinaldi G, **Bossi P**, Dagrada GP, Quattrone P, Cantù G, Licitra L. "Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer" **Oral Oncology 2005; 41: 97-8.**
8. Licitra L, Suardi S, **Bossi P**, Locati LD, Mariani L, Quattrone P, Lo Vullo S, Oggionni M, Olmi P, Cantu G, Pierotti MA, Pilotti S "Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma." . **J Clin Oncol 2004 15; 22: 4901-6.**
9. Locati LD, Guzzo M, **Bossi P**, Massone PP, Conti B, Fumagalli E, Bareggi C, Cantu G, Licitra L. "Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland." **Oral Oncol. 2005; 41: 890-4.**
10. Licitra L, **Bossi P**, D Locati L, Bergamini C. "Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer?" **J Clin Oncol 2005; 23: 7757-8.**
11. Licitra L, Rossini C, **Bossi P**, Locati LD. "Advances in the changing patterns of aetiology of head and neck cancers." **Curr Opin Otolaryngol Head Neck Surg 2006; 14: 95-9.**
12. Licitra L, **Bossi P**, D Locati L. "A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?" **Curr Opin Oncol 2006; 18: 253-7.**
13. **Licitra L**, Locati LD, BossiP. "Biological agents in head and neck cancer" **Ann Oncol 2006; 17 suppl: x45-x48**
14. Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S, Dagrada G, Losa M, Licitra L, **Bossi P**, Staurengo S, Oggionni M, Locati L, Cantu G, Squadrelli M, Carbone A, Pierotti MA, Pilotti S. "Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma". **Clin Cancer Res. 2006; 12: 6643-51.**
15. Licitra L, Perrone F, **Bossi P**, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantù G, Squadrelli M, Quattrone P, Locati LD, Bergamini C, Olmi P, Pierotti MA, Pilotti S. "How High-Risk Human Papillomavirus does affect prognosis of patients with oropharyngeal squamous cell carcinoma primarily treated by surgery". **J. Clin Oncol. 2006; 24: 5630-36.**

16. **Bossi P**, Locati LD, Olmi P, Bergamini C, Liberatoscioli C, Licitra L "Previously irradiated areas spared from skin toxicity induced by cetuximab in 6 patients: implications for the administration of EGFR inhibitors in previously irradiated patients?" . **Ann. Oncol** **2006**, **Oct 30**.
17. **Bossi P**, Locati LD, Licitra L. "Biological agents in head and neck cancer Expert Rev Anticancer Ther. 2007; 7: 1643-50
18. Perrone F, **Bossi P**, Licitra L "TP53 mutations in head and neck cancer".. **N Engl J Med**. **2008**; **358**: **1194-5**
19. **Bossi P**, Locati LD, Licitra L, Tagliabue E. "Folate in head and neck squamous cell cancer chemoprevention: purposely left out?" **J Clin Oncol**. **2008 Jul 10**; **26**:**3463**
20. Licitra L, Locati LD, **Bossi P**. "Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options". **Ann Oncol**. **2008 Sep**; **19 Suppl 7**:**vii200-3**.
21. Locati LD, **Bossi P**, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L "Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study". . **Oral Oncol**. **2008 Sep 17**.
22. Verri C, Roz L, Conte D, Liloglou T, Livio A, Vesin A, Fabbri A, Andriani F, Brambilla C, Tavecchio L, Calarco G, Calabro E, Mancini A, Tosi D, **Bossi P**, Field JK, Brambilla E, Sozzi G "Fragile Histidine Triad Gene Inactivation in Lung Cancer: the European Early Lung Cancer Project." . **Am J Respir Crit Care Med**. **2008 Dec 18**
23. Palazzi M, Orlandi E, **Bossi P**, Pignoli E, Potepan P, Guzzo M, Franceschini M, Scaramellini G, Cantù G, Licitra L, Olmi P, Tomatis S. "Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience" **Int J Radiat Oncol Biol Phys**. **2009**; **74**: **774-80**.
24. Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, Cortelazzi B, Negri T, Tamborini E, Quattrone P, **Bossi P**, Rinaldi G, Bergamini C, Calderone RG, Liberatoscioli C, Licitra L. "Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)." **Oral Oncol**. **2009**; **45**: **986-90**.
25. Fallai C, Perrone F, Licitra L, Pilotti S, Locati L, **Bossi P**, Orlandi E, Palazzi M, Olmi P. "Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status." **Int J Radiat Oncol Biol Phys**. **2009**; **75**:**1053-9**.
26. Perrone F, **Bossi P**, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S, Licitra L. "TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma." **J Clin Oncol** **2010**; **28**:**761-6**.
27. Licitra L, Locati LD, Greco A, Granata R, **Bossi P**. "Multikinase inhibitors in thyroid cancer." **Eur J Cancer**. **2010**; **46**:**1012-8**.
28. **Bossi P**, Granata R, Bergamini C, Mirabile A, Locati L, Licitra L "Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis", by Rades et coll. . **Oral Oncol**. **2010**; **46**: **888**
29. Licitra L, Perrone F, Tamborini E, Bertola L, Ghirelli C, Negri T, Orsenigo M, Filipazzi P, Pastore E, Pompilio M, **Bossi P**, Locati LD, Cantu' G, Scaramellini G, Pilotti S, Tagliabue E. "Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients." **Ann Oncol**. **2011**; **22**:**1886-93**

30. **Bossi P**, Orlandi E, Bergamini C, Locati LD, Granata R, Mirabile A, Parolini D, Franceschini M, Fallai C, Olmi P, Quattrone P, Potepan P, Gloghini A, Miceli R, Mattana F, Scaramellini G, Licitra L. "Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer." **Ann Oncol.** **2011** **22**: 2495-500
31. Perrone F, Gloghini A, Cortelazzi B, **Bossi P**, Licitra L, Pilotti S "Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making." . **Am J Surg Pathol.** **2011**; **35**: 774-7
32. Secondino S, Zecca M, Licitra L, Gurrado A, Schiavetto I, **Bossi P**, Locati L, Schiavo R, Basso S, Baldanti F, Maccario R, Locatelli F, Siena S, Pedrazzoli P, Comoli P. "T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results." **Ann Oncol.** **2012**; **23**: 435-41.
33. Granata R, Miceli R, Orlandi E, Perrone F, Cortelazzi B, Franceschini M, Locati LD, **Bossi P**, Bergamini C, Mirabile A, Mariani L, Olmi P, Scaramellini G, Potepan P, Quattrone P, Ang KK, Licitra L. "Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study." **Ann Oncol.** **2012**; **23**:1832-7.
34. **Bossi P**, Locati LD, Licitra L. Palifermin in prevention of head and neck cancer radiation-induced mucositis: not yet a definitive word on safety and efficacy profile. **J Clin Oncol.** **2012**; **30**: 564-5.
35. Locati LD, **Bossi P**, Licitra L How Many Therapeutic Options Are There for Recurrent or Metastatic Salivary Duct Carcinoma? **J Clin Oncol.** **2012**; **30**: 672.
36. **Bossi P**, Kornek G, Lanzetta G, Rozzi A, Füreder T, Locati L, Licitra L Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. **Head Neck.** **2012**; **35**: 1471-4
37. **Bossi P**, Resteghini C, Perrone F, Cortelazzi B, Pilotti S, Maurichi A, Locati LD, Licitra L. Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. **J Am Acad Dermatol.** **2012**; **67**:e226-8.
38. Orlandi E, Tomatis S, Potepan P, **Bossi P**, Mongioj V, Carrara M, Palazzi M, Franceschini M, Bergamini C, Locati L, Iannacone E, Guzzo M, Ibba T, Crippa F, Licitra L, Pignoli E, Fallai C. Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. **Future Oncol.** **2013**; **9**: 103-14.
39. **Bossi P**, Perrone F, Miceli R, Cantù G, Mariani L, Orlandi E, Fallai C, Locati LD, Cortelazzi B, Quattrone P, Potepan P, Licitra L, Pilotti S. Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. **Oral Oncol.** **2013**; **49**:413-9.
40. Orlandi E, **Bossi P**, Fallai C, Iannacone E, Licitra L. Comments on "Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failure" by Chan et Coll. **Oral Oncology** **2013 Oct**; **49**(10):e38
41. Elting LS, Chang YC, Parelkar P, Boers-Doets CB, Michelet M, Hita G, Rouleau T, Cooksley C, Halm J, Vithala M, **Bossi P**, Escalante C, Brennan MT; On behalf of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. **Support Care Cancer.** **2013**; **21**: 3243-54
42. Saunders DP, Epstein JB, Elad S, Allemano J, **Bossi P**, van de Wetering MD, Rao NG, Potting C, Cheng KK, Freidank A, Brennan MT, Bowen J, Dennis K, Lalla RV; For The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of antimicrobials, mucosal coating agents, anesthetics, and

analgesics for the management of oral mucositis in cancer patients. **Support Care Cancer. 2013; 21: 3191-207**

43. **Bossi P**, Locati LD, Licitra L. Emerging tyrosine kinase inhibitors for head and neck cancer. **Expert Opinion On Emerging Drugs 2013. 2013; 18: 445-59**
44. **Bossi P**, Lo Vullo S, Guzzo M, Mariani L, Granata R, Orlandi E, Locati L, Scaramellini G, Fallai C, Licitra L. Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. **Ann Oncol. 2014; 25: 462-6. doi: 10.1093/annonc/mdt555**
45. **Bossi P**, Orlandi E, Miceli R, Perrone F, Guzzo M, Mariani L, Granata R, Locati L, Fallai C, Cortelazzi B, Pilotti S, Scaramellini G, Gloghini A, Licitra L. Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. **Ann Oncol. 2014; 25: 694-9. doi:10.1093/annonc/mdu004**
46. **Bossi P**, Numico G, De Santis V, Ruo Redda MG, Reali A, Belgioia L, Cossu Rocca M, Orlandi E, Airolidi M, Bacigalupo A, Mazzer M, Saibene G, Russi E. Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. **Support Care Cancer. 2014 Feb 25.**
47. Locati LD, Perrone F, Cortelazzi B, Imbimbo M, **Bossi P**, Potepan P, Civelli E, Rinaldi G, Quattrone P, Licitra L, Pilotti S. Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. **Cancer Biol Ther. 2014 Mar 11;15(6).**
48. Ripamonti CI, **Bossi P**, Santini D, Fallon M. Pain related to cancer treatments and diagnostic procedures: a no man's land? **Ann Oncol. 2014; 25:1097-106**
49. De Cecco L, **Bossi P**, Locati L, Canevari S and Licitra L. Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. **Annals of Oncology, 2014; 25:1628-35**
50. Granata R, **Bossi P**, Bertulli R, Saita L. Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse. **Pain Med. 2014 May;15(5):758-61**
51. **Bossi P**, Locati L, Bergamini C, Mirabile A, Granata R, Imbimbo M, Resteghini C, Licitra L. Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. **Oral Oncol. 2014 Sep;50(9):884-7.**
52. Locati LD, Perrone F, Cortelazzi B, Lo Vullo S, **Bossi P**, Dagrada G, Quattrone P, Bergamini C, Potepan P, Civelli E, Fallai C, Pilotti S, Licitra L. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed AR-positive salivary gland cancers. **Head Neck. 2014 Dec 18. doi: 10.1002/hed.23940.**
53. Cortelazzi B, Verderio P, Ciniselli CM, Pizzamiglio S, **Bossi P**, Gloghini A, Gualeni AV, Volpi CC, Locati L, Pierotti MA, Licitra L, Pilotti S, Perrone F. Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. **J Oral Pathol Med. 2014 Dec 14. doi: 10.1111/jop.12301.**
54. Orlandi E, Takanen S, Giandini T, Iannacone E, Fontanella W, Locati L, Carrara M, **Bossi P**, Bergamini C, Granata R, Tombolini V, Ibba T, Licitra L, Pignoli E, Fallai C. Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review **Future Oncol. 2014 Nov;10(14):2111-20.**
55. Orlandi E, Giandini T, Iannacone E, De Ponti E, Carrara M, Mongioj V, Stucchi C, Tana S, **Bossi P**, Licitra L, Fallai C, Pignoli E. Radiotherapy for unresectable sinonasal cancers: dosimetric comparison of

intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy **Radiother Oncol.** 2014 Nov;**113(2):260-6.**

56. Saba NF, Haigentz M Jr, Vermorken JB, Strojan P, **Bossi P**, Rinaldo A, Takes RP, Ferlito A. Prevention of head and neck squamous cell carcinoma: removing the "chemo" from "chemoprevention". **Oral Oncol.** 2015 Feb;**51(2):112-8.**
57. Roila F, Ripamonti CI, Antonuzzo A, **Bossi P** NICSO: Network Italiano Cure di Supporto in Oncologia-- Italian Network for Supportive Care in Oncology. **Support Care Cancer.** 2015 Jan;**23(1):11-2**
58. Pricl S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M, Licitra L, Pilotti S, **Bossi P**, Perrone F. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. **Mol Oncol.** 2015 Feb;**9(2):389-97.**
59. Mirabile A, Numico G, Russi EG, **Bossi P**, Crippa F, Bacigalupo A, De Sanctis V, Musso S, Merlotti A, Ghi MG, Merlano MC, Licitra L, Moretto F, Denaro N, Caspiani O, Buglione M, Pergolizzi S, Cascio A, Bernier J, Raber-Durlacher J, Vermorken JB, Murphy B, Ranieri MV, Dellinger RP. Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. **Crit Rev Oncol Hematol.** 2015 Mar 19. pii: **S1040-8428**
60. De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, **Bossi P**, Locati L, Licitra L, Canevari S. Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. **Oncotarget.** 2015 Mar 20.
61. Greco A, Orlandi E, Mirabile A, Takanen S, Fallai C, Iacovelli NA, Rimedio A, Russi E, Sala M, Monzani D, Rosenthal DI, Gunn GB, Steca P, Licitra L, **Bossi P**. Italian version of the M.D. Anderson Symptom Inventory-Head and Neck Module: linguistic validation. **Support Care Cancer.** 2015 Mar 21.
62. Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M, **Bossi P**, Worden FP, Langendijk JA, Eisbruch A, Mendenhall WM, Lee AW, Harrison LB, Bradford CR, Smee R, Silver CE, Rinaldo A, Ferlito A. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. **Head Neck.** 2015 Mar 3. doi: **10.1002/hed.24026**
63. Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, Hicks SC, McDonald TO, Ow TJ, Alves MO, Pickering CR, Skinner HD, Zhao M, Sturgis EM, Kies MS, El-Naggar A, Perrone F, Licitra L, **Bossi P**, Kimmel M, Frederick MJ, Lichtarge O, Myers JN. Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. **Cancer Res.** 2015 Apr 1;**75(7):1205-15.**
64. Greco A, Orlandi E, Mirabile A, Takanen S, Fallai C, Iacovelli NA, Rimedio A, Russi E, Sala M, Monzani D, Rosenthal DI, Gunn GB, Steca P, Licitra L, **Bossi P**. Italian version of the M.D. Anderson Symptom Inventory-Head and Neck Module: linguistic validation. **Support Care Cancer.** 2015 Dec;**23(12):3465-72.**
65. Mirabile A, Numico G, Russi EG, **Bossi P**, Crippa F, Bacigalupo A, De Sanctis V, Musso S, Merlotti A, Ghi MG, Merlano MC, Licitra L, Moretto F, Denaro N, Caspiani O, Buglione M, Pergolizzi S, Cascio A, Bernier J, Raber-Durlacher J, Vermorken JB, Murphy B, Ranieri MV, Dellinger RP. Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. **Crit Rev Oncol Hematol.** 2015 Aug;**95(2):191-213**
66. De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, **Bossi P**, Locati L, Licitra L, Canevari S. Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. **Oncotarget.** 2015 Apr 20;**6(11):9627-42.**
67. **Bossi P**, Lucchesi M, Antonuzzo A. Gastrointestinal toxicities from targeted therapies: measurement, duration and impact. **Curr Opin Support Palliat Care.** 2015 Jun;**9(2):163-7**

68. Buzzacchino S, Lanzola G, **Bossi P**, Licitra L, Quaglini S. A mobile application supporting outpatient treatment and follow-up. **Stud Health Technol Inform.** **2015;210:788-92**
69. Mirabile A, Vismara C, Crippa F, **Bossi P**, Locati L, Bergamini C, Granata R, Resteghini C, Conte E, Morelli D, Scarpellini P, Licitra L. Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. **Head Neck.** **2015 Jun 3.**
70. Proserpio T, Ferrari A, Lo Vullo S, Massimino M, Clerici CA, Veneroni L, Bresciani C, Casali PG, Ferrari M, **Bossi P**, Galmozzi G, Pierantozzi A, Licitra L, Marceglia S, Mariani L. Hope in cancer patients: the relational domain as a crucial factor. **Tumori.** **2015 Jul-Aug;101(4):447-54.**
71. Pessi MA, Necchi A, **Bossi P**, Resteghini C, Giannatempo P, Ferrari L, Zilembo N, Ripamonti CI. Nausea and vomiting during the first 3 intercycle periods in chemo-naive cancer patients receiving moderately/highly emetogenic therapy. **Tumori.** **2015 Nov 14;101(6):692-6.**
72. Schindler A, Denaro N, Russi EG, Pizzorni N, **Bossi P**, Merlotti A, Spadola Bissetti M, Numico G, Gava A, Orlandi E, Caspiani O, Buglione M, Alterio D, Bacigalupo A, De Sanctis V, Pavanato G, Ripamonti C, Merlano MC, Licitra L, Sanguineti G, Langendijk JA, Murphy B. Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. **Crit Rev Oncol Hematol.** **2015 Nov;96(2):372-84.**
73. Russi EG, Moretto F, Rampino M, Benasso M, Bacigalupo A, De Sanctis V, Numico G, **Bossi P**, Buglione M, Lombardo A, Airoidi M, Merlano MC, Licitra L, Denaro N, Pergolizzi S, Pinto C, Bensadoun RJ, Girolomoni G, Langendijk JA. Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. **Crit Rev Oncol Hematol.** **2015 Oct;96(1):167-82.**
74. **Bossi P**, Saba NF, Vermorken JB, Strojjan P, Pala L, de Bree R, Rodrigo JP, Lopez F, Hanna EY, Haigentz M, Takes RP, Slootweg PJ, Silver CE, Rinaldo A, Ferlito A. The role of systemic therapy in the management of sinonasal cancer: A critical review. **Cancer Treat Rev.** **2015 Dec;41(10):836-43.**
75. **Bossi P**, Orlandi E, Licitra L. Comment on 'Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base'. **Br J Cancer.** **2015 Dec 1;113(11):1638-9**
76. Buglione M, Cavagnini R, Di Rosario F, Sottocornola L, Maddalo M, Vassalli L, Grisanti S, Salgarello S, Orlandi E, Paganelli C, Majorana A, Gastaldi G, **Bossi P**, Berruti A, Pavanato G, Nicolai P, Maroldi R, Barasch A, Russi EG, Raber-Durlacher J, Murphy B, Magrini SM. Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. **Crit Rev Oncol Hematol.** **2016 Jan;97:131-42.**
77. Marta GN, Riera R, **Bossi P**, Zhong LP, Licitra L, Macedo CR, de Castro G Junior, Carvalho AL, William WN Jr, Kowalski LP. Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. **Eur J Cancer.** **2015 Nov;51(17):2596-2603. doi: 10.1016/j.ejca.2015.08.007.**
78. **Bossi P**, Farina D, Gatta G, Lombardi D, Nicolai P, Orlandi E. Paranasal sinus cancer. **Crit Rev Oncol Hematol.** **2015 Oct 19. pii: S1040-8428(15)30049-4.**
79. Castelnovo P, Turri-Zanoni M, Battaglia P, Antognoni P, **Bossi P**, Locatelli D. Sinonasal Malignancies of Anterior Skull Base: Histology-driven Treatment Strategies. **Otolaryngol Clin North Am.** **2016 Feb;49(1):183-200.**
80. Mirabile A, Airoidi M, Ripamonti C, Bolner A, Murphy B, Russi E, Numico G, Licitra L, **Bossi P**. Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. **Crit Rev Oncol Hematol.** **2015 Dec 3. pii: S1040-8428(15)30081-0.**

81. Bergamini C, Locati L, **Bossi P**, Granata R, Alfieri S, Resteghini C, Imbimbo M, Fallai C, Orlandi E, Tana S, Iacovelli NA, Guzzo M, Ibba T, Colombo S, Bianchi R, Pizzi N, Fontanella W, Licitra L. Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? **Oral Oncol.** 2016 Jan 13. pii: **S1368-8375(16)00002-6**.
82. Alfieri S, Ripamonti CI, Marceglia S, Orlandi E, Iacovelli NA, Granata R, Cavallo A, Pozzi P, Boffi R, Bergamini C, Imbimbo M, Pala L, Resteghini C, Mirabile A, Locati LD, Licitra L, **Bossi P**. Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. **Head Neck.** 2016 Apr;**38 Suppl 1:E1521-7**. doi: 10.1002/hed.24272. Epub 2016 Feb 5. PubMed PMID: 26849016.
83. **Bossi P**, Bergamini C, Siano M, Cossu Rocca M, Sponghini AP, Favales F, Giannoccaro M, Marchesi E, Cortelazzi B, Perrone F, Pilotti S, Locati LD, Licitra L, Canevari S, De Cecco L. Functional genomics uncover the biology behind the responsiveness of head and neck squamous cell cancer patients to cetuximab. **Clin Cancer Res.** 2016 Feb 26. pii: **clincanres.2547.2015**.
84. De Sanctis V, **Bossi P**, Sanguineti G, Trippa F, Ferrari D, Bacigalupo A, Ripamonti CI, Buglione M, Pergolizzi S, Langendijk JA, Murphy B, Raber-Durlacher J, Russi EG, Lalla RV. Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. **Crit Rev Oncol Hematol.** 2016 Apr;**100:147-66**. doi:**10.1016/j.critrevonc.2016.01.010**. Epub 2016 Feb 1. Review. PubMed PMID: 26947812.
85. Pala L, Bergamini C, Imbimbo M, Granata R, Locati L, Alfieri S, Licitra L, **Bossi P**. Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report. **Tumori.** 2016 Mar 14;**0**. doi: **10.5301/tj.5000485**. PubMed PMID: 26979243.
86. **Bossi P**, Alfieri S. Investigational drugs for head and neck cancer. **Expert Opin Investig Drugs.** 2016 Jul;**25(7):797-810**. doi: 10.1080/13543784.2016.1175435. Epub 2016 Apr 25. PubMed PMID: 27054910.
87. Buglione M, Cavagnini R, Di Rosario F, Maddalo M, Vassalli L, Grisanti S, Salgarello S, Orlandi E, **Bossi P**, Majorana A, Gastaldi G, Berruti A, Trippa F, Nicolai P, Barasch A, Russi EG, Raber-Durlacher J, Murphy B, Magrini SM. Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. **Crit Rev Oncol Hematol.** 2016 Jun;**102:47-54**. doi: 10.1016/j.critrevonc.2016.03.012. Epub 2016 Mar 11. Review. PubMed PMID: 27061883.
88. **Bossi P**, Cortinovis D, Cossu Rocca M, Roila F, Seminara P, Fabi A, Canova S, Verri E, Fatigoni S, Iannace A, Macchi F, Ripamonti C. Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and Vomiting. **J Altern Complement Med.** 2016 Jun;**22(6):486-8**. doi:10.1089/acm.2015.0315. Epub 2016 Apr 26. PubMed PMID: 27115042; PubMed Central PMCID: PMC4921900.
89. Perrone F, **Bossi P**, Cortelazzi B, Dagrada GP, Paielli N, Licitra L, Pilotti S. Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. **Oral Oncol.** 2016 Jul;**58:e4-5**. doi: 10.1016/j.oraloncology.2016.05.015. Epub 2016 Jun 1. PubMed PMID: 27262592.
90. Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, **Bossi P**, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS; Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer, 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. **Support Care Cancer.** 2016 Jun 25. [Epub ahead of print] Review. PubMed PMID: 27344327.
91. **Bossi P**, Alfieri S. The Benefit of a Multidisciplinary Approach to the Patient Treated with (Chemo) Radiation for Head and Neck Cancer. **Curr Treat Options Oncol.** 2016 Oct;**17(10):53**. doi: 10.1007/s11864-016-0431-3. Review. PubMed PMID: 27520784.

92. **Bossi P**, Resteghini C, Paielli N, Licitra L, Pilotti S, Perrone F. Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. *Oncotarget*. 2016 Aug 19. doi: 10.18632/oncotarget.11413. [Epub ahead of print] PubMed PMID: 27556186.
93. Spreafico A, Huang SH, Xu W, Granata R, Liu CS, Waldron JN, Chen E, Ringash J, Bayley A, Chan KK, Hope AJ, Cho J, Razak AA, Hansen A, Jang R, Perez-Ordóñez B, Weinreb I, **Bossi P**, Orlandi E, Licitra LF, Song Y, O'Sullivan B, Siu LL, Kim J. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. *Eur J Cancer*. 2016 Sep 23;67:174-182. doi: 10.1016/j.ejca.2016.08.013. [Epub ahead of print] PubMed PMID: 27669504.
94. Spreafico A, Huang SH, Xu W, Granata R, Liu CS, Waldron JN, Chen E, Ringash J, Bayley A, Chan KK, Hope AJ, Cho J, Razak AA, Hansen A, Jang R, Perez-Ordóñez B, Weinreb I, **Bossi P**, Orlandi E, Licitra LF, Song Y, O'Sullivan B, Siu LL, Kim J. - *Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma* - **Eur J Cancer**. 2016 Nov;67:174-182. doi: 10.1016/j.ejca.2016.08.013. Epub 2016 Sep 24. PMID: 27669504
95. **Bossi P**, Resteghini C, Paielli N, Licitra L, Pilotti S, Perrone F.- *Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma* - *Oncotarget*. 2016 Nov 8;7(45):74362-74379. doi: 10.18632/oncotarget.11413. Review. PMID: 27556186 Free PMC Article
96. Valenti C, Pozzi P, Busia A, Mazza R, **Bossi P**, De Marco C, Ruprecht AA, Borgini A, Boffi R. - *Respiratory illness and air pollution from the steel industry: the case of Piquiá de Baixo, Brazil (Preliminary report)* - *Multidiscip Respir Med*. 2016 Nov 9;11:41. eCollection 2016. PMID: 27833748 Free PMC Article
97. Pala L, Bergamini C, Imbimbo M, Granata R, Locati L, Alfieri S, Licitra L, **Bossi P**.- *Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report*. - *Tumori*. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000485. PMID: 26979243
98. **Bossi P**, Bergamini C, Miceli R, Cova A, Orlandi E, Resteghini C, Locati L, Alfieri S, Imbimbo M, Granata R, Mariani L, Iacovelli NA, Huber V, Cavallo A, Licitra L, Rivoltini L.- *Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy* - *Int J Radiat Oncol Biol Phys*. 2016 Dec 1;96(5):959-966. doi: 10.1016/j.ijrobp.2016.08.047. Epub 2016 Sep 6. PMID: 27745982
99. Locati LD, Perrone F, Cortelazzi B, Bergamini C, **Bossi P**, Civelli E, Morosi C, Lo Vullo S, Imbimbo M, Quattrone P, Dagrada GP, Granata R, Resteghini C, Mirabile A, Alfieri S, Orlandi E, Mariani L, Saibene G, Pilotti S, Licitra L. - *A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact*. - **Eur J Cancer**. 2016 Dec;69:158-165. doi: 10.1016/j.ejca.2016.09.022. Epub 2016 Nov 5. PMID: 27821319
100. De Cecco L, Giannoccaro M, Marchesi E, **Bossi P**, Favales F, Locati LD, Licitra L, Pilotti S, Canevari S.- *Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer* - **Genes (Basel)**. 2017 Jan 14;8(1). pii: E35. doi: 10.3390/genes8010035. PMID: 28098823 Free PMC Article
101. Alfieri S, Granata R, Bergamini C, Resteghini C, **Bossi P**, Licitra LF, Locati LD. - *Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?* **Oral Oncol**. 2017 Mar;66:58-63. doi: 10.1016/j.oraloncology.2016.12.016. Epub 2017 Jan 19. Review. PMID: 28249649
102. Meregaglia M, Cairns J, Alfieri S, Favales F, Mazzitelli D, Orlandi E, Licitra L, **Bossi P**. - *Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling*.- **Value Health**. 2017 Jun;20(6):799-808. doi: 10.1016/j.jval.2017.01.012. Epub 2017 Mar 31.- PMID: 28577698
103. Iacovelli NA, Naimo S, Bonfantini F, Cavallo A, **Bossi P**, Fallai C, Pignoli E, Alfieri S, Bergamini C, Favales F, Orlandi E. - *Preemptive treatment with Xonrid®, a medical device to reduce radiation induced dermatitis in head and neck cancer patients receiving curative treatment: a pilot study*.-

Support Care Cancer. 2017 - un;25(6):1787-1795. doi: 10.1007/s00520-017-3569-z. Epub 2017 Jan 20.- PMID: 28108819

104. Siano M, Infante G, Resteghini C, Cau MC, Alfieri S, Bergamini C, Granata R, Miceli R, Locati L, Licitra L, **Bossi P.** - *Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy* - **Oral Oncol.** 2017 Jun;69:33-37. doi: 10.1016/j.oraloncology.2017.04.002. Epub 2017 Apr 9. - PMID: 28559018
105. **Bossi P,** Cortinovis D, Fatigoni S, Cossu Rocca M, Fabi A, Seminara P, Ripamonti C, Alfieri S, Granata R, Bergamini C, Agustoni F, Bidoli P, Nolè F, Pessi MA, Macchi F, Michellini L, Montanaro F, Roila F.- A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high dose cisplatin.- **Ann Oncol.** 2017 Jun 28. doi: 10.1093/annonc/mdx315. [Epub ahead of print] PMID: 28666335
106. Orlandi E, **Bossi P.**- Toward Personalized Cancer Care for Elderly Head and Neck Cancer Patients.- *Int J Radiat Oncol Biol Phys.* 2017 Jul 15;98(4):965-966. doi: 10.1016/j.ijrobp.2016.11.001. No abstract available. PMID: 28602420
107. Alfieri S, Iacovelli NA, Marceglia S, Lasorsa I, Resteghini C, Taverna F, Mazzocchi A, Orlandi E, Guzzo M, Bianchi R, Fanti D, Pala L, Racca S, Dvir R, Quattrone P, Gloghini A, Volpi CC, Granata R, Bergamini C, Locati L, Licitra L, **Bossi P.** Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. - **Oncotarget.** 2017 Jul 18;8(29):47780-47789. doi: 10.18632/oncotarget.17822. PMID:28562354 Free Article

Capitoli di Volumi:

“Oropharyngeal cancers”

Licitra L, **Bossi P,** Locati L et al. in “Head & Neck surgery”, Jaypee Brothers Medical Publishers 2009: 970-977

“Role of HPV infections in head and neck cancer”

Licitra L, Locati LD, Bergamini C, **Bossi P.** Editor: Robert Haddad, 2011

“Carcinoma del rinofaringe”

Orlandi E, **Bossi P.** Tumori della testa e del collo. Editor: Lisa Licitra, Patrizia Olmi, 2011

“Carcinoma dei seni paranasali”

Paolo Castelnuovo, Maurizio Bignami, Paolo Battaglia, Stefania Gallo, Pietro Gabriele, Elisabetta Garibaldi, Barbara Carau, **Paolo Bossi.** Tumori della testa e del collo. Editor: Lisa Licitra, Patrizia Olmi, 2011

“Role of chemotherapy in thyroid cancer”

Bossi P, Locati LD. In “Thyroid cancer: from emergent biotechnologies to clinical practice guidelines” ed. Carpi A, Mechanick JI. CRC press 2011; 313-318

“Thyroid cancer”

Locati LD, Greco A, Borrello MG, **Bossi P.** et al. in “Biotargets of cancer in current clinical practice”, ed. Springer, 2012: 61-91

“Oropharyngeal cancers”

Locati LD, **Bossi P,** Fallai C, Licitra L in “Head & Neck surgery”, Jaypee Brothers Medical Publishers updated for the new edition 2013